Prognostic significance of psoas muscle index in male hepatocellular carcinoma patients treated with immune checkpoint inhibitors and tyrosine kinase inhibitors

Luo, Ning; Li, Hu; Luo, Yindeng; Hu, Peng; Liang, Luwen; Zhang, Rong; Zhang, Dazhi; Cai, Dachuan; Kang, Juan

doi:10.1080/21645515.2023.2258567

Cited by 4 publications

(2 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another recent study conducted by Luo et al investigated the prognostic value of a low PMI in patients with HCC undergoing combination therapy with immune checkpoint inhibitors and tyrosine kinase inhibitors. Sarcopenia was an independent negative prognostic factor in the long-term outcomes, being associated with the risk of death at both 1 year and at the end of the follow-up [73].…”

Section: Sarcopenia In Hcc Patientsmentioning

confidence: 94%

Ultrasound Evaluation of Sarcopenia in Patients with Hepatocellular Carcinoma: A Faster and Easier Way to Detect Patients at Risk

Esposto,

Borriello,

Galasso

et al. 2024

Diagnostics

View full text Add to dashboard Cite

The condition of sarcopenia, defined as a progressive loss of musculoskeletal mass and muscular strength, is very common in patients with hepatocellular carcinoma (HCC) and presents a remarkable association with its prognosis. Thus, the early identification of sarcopenic patients represents one of the potential new approaches in the global assessment of HCC, and there is increasing interest regarding the potential therapeutic implications of this condition. The gold standard for the quantification of muscle mass is magnetic resonance imaging (MRI) or computed tomography (CT), but these techniques are not always feasible because of the high-cost equipment needed. A new possibility in sarcopenia identification could be muscle ultrasound examination. The measurement of specific parameters such as the muscle thickness, muscular fascicles length or pennation angle has shown a good correlation with CT or MRI values and a good diagnostic accuracy in the detection of sarcopenia. Recently, these results were also confirmed specifically in patients with chronic liver disease. This review summarizes the role of imaging for the diagnosis of sarcopenia in patients with HCC, focusing on the advantages and disadvantages of the diagnostic techniques currently validated for this aim and the future perspectives for the identification of this condition.

show abstract

Section: Sarcopenia In Hcc Patientsmentioning

confidence: 94%

Ultrasound Evaluation of Sarcopenia in Patients with Hepatocellular Carcinoma: A Faster and Easier Way to Detect Patients at Risk

Esposto,

Borriello,

Galasso

et al. 2024

Diagnostics

View full text Add to dashboard Cite

show abstract

“…In China, 60-80% of liver cancer patients are in the middle and advanced stages at the time of diagnosis, which seriously affects the clinical outcome of patients. Consequently, early screening, diagnosis, and treatment are imperative for liver cancer [1,2].…”

Section: Introductionmentioning

confidence: 99%

The value of HIFI model based on cell-free DNA genomic features in early diagnosis and prediction of hepatocellular carcinoma

Li,

Lu,

Wang

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Background The detection of cell-free DNA (cfDNA) is a promising early diagnosis method for hepatocellular carcinoma (HCC). We validated the cfDNA-based comprehensive diagnostic model (HIFI) and explored its value in the early diagnosis and prediction of HCC. Methods cfDNA detection was performed in 126 patients, the results of HIFI were obtainedand compared with HCC markers. Moreover, we conducted a comparison between the predictive ability of aMAP score and the HIFI model for HCC at 10 months of follow-up. Results Chi-square test and Kappa analysis showed that the diagnostic consistency between HIFI model and traditional methods was significantly higher than that of AFP and PIVKA-II (Kappa=0.461 vs 0.251 vs 0.287, P≤0.05). Moreover, the consistency of HIFI model combined with PIVKA-II was higher than that of AFP combined with PIVKA-II and HIFI model combined with AFP (Kappa=0.564 vs 0.267 vs 0.317, P≤0.05). We compared HIFI model with aMAP score at 10 months, the sensitivity, specificity, PPV and NPV of HIFI model in predicting HCC was 70.59%, 90.32%, 66.67% and 91.80%. When 50/60 is set as the cut-off value of aMAP score, the sensitivity, specificity, PPV and NPV was 94.12 / 76.47%, 29.03 / 72.58%, 26.67 / 43.33% and 94.74 / 91.84%. Conclusions The study demonstrated the superiority of the cfDNA-based HIFI model as a method of early warning and diagnosis of HCC. Moreover, the predictive efficacy of the HIFI model remained high at 10 months, in terms of specificity and PPV, the HIFI model was better than aMAP score.

show abstract

A nomogram incorporating Psoas muscle index for predicting tumor recurrence after liver transplantation: A retrospective study in an Eastern Asian population

Yang,

Huang,

Chen

et al. 2024

Heliyon

View full text Add to dashboard Cite

Prognostic significance of psoas muscle index in male hepatocellular carcinoma patients treated with immune checkpoint inhibitors and tyrosine kinase inhibitors

Cited by 4 publications

References 64 publications

Ultrasound Evaluation of Sarcopenia in Patients with Hepatocellular Carcinoma: A Faster and Easier Way to Detect Patients at Risk

Ultrasound Evaluation of Sarcopenia in Patients with Hepatocellular Carcinoma: A Faster and Easier Way to Detect Patients at Risk

The value of HIFI model based on cell-free DNA genomic features in early diagnosis and prediction of hepatocellular carcinoma

A nomogram incorporating Psoas muscle index for predicting tumor recurrence after liver transplantation: A retrospective study in an Eastern Asian population

Contact Info

Product

Resources

About